Daniel Busby
Stock Analyst at RBC Capital
(2.72)
# 2,079
Out of 5,012 analysts
6
Total ratings
66.67%
Success rate
22.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Busby
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $160 → $40 | $4.61 | +767.68% | 2 | May 25, 2022 | |
PFE Pfizer | Maintains: Sector Perform | $43 → $44 | $26.27 | +67.49% | 1 | Jun 17, 2021 | |
MNKD MannKind | Initiates: Sector Perform | $5 | $5.65 | -11.50% | 2 | May 14, 2021 | |
ABBV AbbVie | Reiterates: Outperform | $135 | $232.83 | -42.02% | 1 | May 3, 2021 |
Verrica Pharmaceuticals
May 25, 2022
Downgrades: Sector Perform
Price Target: $160 → $40
Current: $4.61
Upside: +767.68%
Pfizer
Jun 17, 2021
Maintains: Sector Perform
Price Target: $43 → $44
Current: $26.27
Upside: +67.49%
MannKind
May 14, 2021
Initiates: Sector Perform
Price Target: $5
Current: $5.65
Upside: -11.50%
AbbVie
May 3, 2021
Reiterates: Outperform
Price Target: $135
Current: $232.83
Upside: -42.02%